Get the Stockscreener App
1.19
2.46%
-0.03
Pre-market:
1.22
0.03
+2.52%
Elutia Inc stock is traded at $1.19, with a volume of 522.27K.
It is down -2.46% in the last 24 hours and up +19.94% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$1.22
Open:
$1.24
24h Volume:
522.27K
Relative Volume:
1.45
Market Cap:
$50.81M
Revenue:
$24.38M
Net Income/Loss:
$-53.95M
P/E Ratio:
-0.4818
EPS:
-2.47
Net Cash Flow:
$-23.31M
1W Performance:
+9.17%
1M Performance:
+19.94%
6M Performance:
-40.80%
1Y Performance:
-59.80%
1-Day Range:
$1.18
$1.385
1-Week Range:
$1.08
$1.385
52-Week Range:
$0.50
$3.46
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.19 | 52.10M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia regains compliance with Nasdaq listing requirements - Investing.com
Elutia regains Nasdaq compliance after meeting minimum bid price and MVLS - TradingView
Elutia Regains Full Nasdaq Compliance, Strengthening Listing Status - TipRanks
Elutia Regains Compliance with Nasdaq Listing Requirements - Bitget
Elutia (NASDAQ: ELUT) regains full Nasdaq listing compliance after bid price, value breach - Stock Titan
Elutia keeps its Nasdaq spot after meeting price, value rules - Stock Titan
Elutia names Pete Ligotti chief commercial officer - Investing.com
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market - Bitget
New Elutia CCO targets 15–20% infection rates in breast reconstruction - Stock Titan
ELUT Should I Buy - Intellectia AI
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026 - Bitget
Elutia schedules March 11 webcast for Q4 2025 financials - Stock Titan
ELUT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Interview with the President and CEO: Elutia Inc. (NASDAQ:ELUT) - The Wall Street Transcript
Short Squeeze: What is the PEG ratio of Brookdale Senior Living IncStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification - HRTech Series
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™ - The Manila Times
Risks Report: Is Elutia Inc subject to activist investor interest2025 Technical Overview & Expert Approved Momentum Ideas - baoquankhu1.vn
Targets Report: What is the Moat Score of Elutia IncJuly 2025 Earnings & Technical Confirmation Trade Alerts - baoquankhu1.vn
Alyeska discloses 3.18% Elutia (ELUT) stake in amended 13G - Stock Titan
Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Short Covering: Is Elutia Inc benefiting from innovation trendsJuly 2025 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
What is Elutia Inc. s debt to equity ratioJuly 2025 Closing Moves & Safe Capital Growth Plans - mfd.ru
Nantahala reports 9.99% Elutia (ELUT) ownership stake in 13G/A - Stock Titan
CEO Moves: Is Elutia Inc benefiting from innovation trendsInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Elutia Inc. stock outperform value stocksGap Down & Technical Pattern Based Buy Signals - mfd.ru
Options Flow: Can Elutia Inc be recession proofPrice Action & Technical Confirmation Alerts - baoquankhu1.vn
Elutia Loses US$4.6m Market Value But Insiders See Windfall Of US$60k - simplywall.st
Insider Spends US$74k Buying More Shares In Elutia - Yahoo Finance
Aug Summary: What is the Moat Score of Elutia IncStop Loss & Smart Allocation Stock Tips - baoquankhu1.vn
Trend Report: Is Elutia Inc forming a breakout patternJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know - sharewise.com
Insider Buying: Guido Neels Acquires 20,000 Shares of Elutia Inc (ELUT) - GuruFocus
Elutia Inc. director Neels buys $20,800 in shares By Investing.com - Investing.com Australia
Elutia Inc. director Neels buys $20,800 in shares - Investing.com
Elutia launches $15M securities offering - MSN
Elutia Inc: director Neels buys $31.8k in company stock - Investing.com India
Elutia Inc: director Neels buys $31.8k in company stock By Investing.com - Investing.com South Africa
Insider Buying: Guido Neels Acquires 30,000 Shares of Elutia Inc (ELUT) - GuruFocus
Aug Movers: Can OPCH scale operations efficientlyMarket Performance Report & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Elutia sees Q4 net sales of $3.3M - MSN
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Elutia reports 16% revenue growth, advances breast reconstruction product By Investing.com - Investing.com Canada
Elutia reports 16% revenue growth, advances breast reconstruction product - Investing.com
Elutia (ELUT) Strengthens Position with Drug-Eluting Platform - GuruFocus
Elutia reports preliminary fourth quarter 2025 results, strengthened financial position, and upcoming Nxt-41X milestones - marketscreener.com
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, And Upcoming Nxt-41X Milestones - TradingView — Track All Markets
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones - The Manila Times
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):